Drug tested to keep aggressive lung cancer at bay
NCT ID NCT02863055
Summary
This study tested whether a drug called nintedanib could help control malignant pleural mesothelioma, a serious cancer of the lung lining, after patients completed initial chemotherapy. The trial compared nintedanib against a placebo (inactive pill) in patients whose cancer had not worsened after first-line treatment. The goal was to see if taking nintedanib daily could delay the cancer's return or progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Manchester University NHS Foundation Trust - UHSM-Wythenshawe Hospital
Wythenshawe, Manchester, M23 9LT, United Kingdom
-
NHS South Tyneside-South Tyneside District Hospital
South Shields, United Kingdom
-
Ospedale San Paolo
Milan, Italy
-
Royal Marsden Hospital
Chelsea, United Kingdom
-
Royal Marsden Hospital
Sutton, United Kingdom
-
Royal Marsden Hospital - Kingston
Kingston, United Kingdom
-
Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital
Sheffield, United Kingdom
-
UZ Antwerpen
Antwerp, Belgium
-
UZ Gent
Ghent, Belgium
Conditions
Explore the condition pages connected to this study.